KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Retained Earnings (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Retained Earnings for 16 consecutive years, with -$2.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 84.24% year-over-year to -$2.4 billion, compared with a TTM value of -$2.4 billion through Dec 2025, up 84.24%, and an annual FY2025 reading of -$2.4 billion, up 84.24% over the prior year.
  • Retained Earnings was -$2.4 billion for Q4 2025 at Teva Pharmaceutical Industries, up from -$2.5 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$47.0 million in Q1 2024 and bottomed at -$15.2 billion in Q4 2024.
  • Average Retained Earnings over 5 years is -$4.8 billion, with a median of -$2.4 billion recorded in 2025.
  • The sharpest move saw Retained Earnings surged 98.03% in 2024, then tumbled 31725.53% in 2025.
  • Year by year, Retained Earnings stood at -$2.3 billion in 2021, then fell by 10.55% to -$2.5 billion in 2022, then soared by 89.42% to -$266.0 million in 2023, then plummeted by 5604.14% to -$15.2 billion in 2024, then soared by 84.24% to -$2.4 billion in 2025.
  • Business Quant data shows Retained Earnings for TEVA at -$2.4 billion in Q4 2025, -$2.5 billion in Q3 2025, and -$2.4 billion in Q2 2025.